Ngā hua rapu - Sumanta K. Pal

Whakamahine hua
  1. 1
    Differentiating mTOR inhibitors in renal cell carcinoma

    Differentiating mTOR inhibitors in renal cell carcinoma mā Sumanta K. Pal, David I. Quinn

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future

    Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future mā Sumanta K. Pal, Naomi B. Haas

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    CYP17 inhibitors in prostate cancer: latest evidence and clinical potential

    CYP17 inhibitors in prostate cancer: latest evidence and clinical potential mā Anitha Alex, Sumanta K. Pal, Neeraj Agarwal

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    The role of peroxisome proliferator-activated receptor gamma in prostate cancer

    The role of peroxisome proliferator-activated receptor gamma in prostate cancer mā JeremyO Jones, Catherine Elix, SumantaK Pal

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    End-of-Life Care Among Patients With Metastatic Renal Cell Carcinoma: Importance of a Patient-Centric Focus in Clinical Decision Making

    End-of-Life Care Among Patients With Metastatic Renal Cell Carcinoma: Importance of a Patient-Centric Focus in Clinical Decision Making mā Cristiane Decat Bergerot, Sandy Liu, Sumanta K. Pal

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era

    Disease-Specific Survival in De Novo Metastatic Renal Cell Carcinoma in the Cytokine and Targeted Therapy Era mā Sumanta K. Pal, Rebecca A. Nelson, Nicholas J. Vogelzang

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Male breast cancer: An update in diagnosis, treatment and molecular profiling

    Male breast cancer: An update in diagnosis, treatment and molecular profiling mā Susan Onami, Melanie Ozaki, Joanne Mortimer, Sumanta K. Pal

    I whakaputaina 2010
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Renal cell carcinoma: An update for the practicing urologist

    Renal cell carcinoma: An update for the practicing urologist mā Sumanta K. Pal, Paulo Gustavo Bergerot, Robert A. Figlin

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Tivozanib: current status and future directions in the treatment of solid tumors

    Tivozanib: current status and future directions in the treatment of solid tumors mā Sumanta K. Pal, Paulo Gustavo Bergerot, Robert A. Figlin

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape

    Targeted Therapies for Non–Small Cell Lung Cancer: An Evolving Landscape mā Sumanta K. Pal, Robert A. Figlin, Karen L. Reckamp

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Triple negative breast cancer: unmet medical needs

    Triple negative breast cancer: unmet medical needs mā Sumanta K. Pal, Barrett H. Childs, Mark D. Pegram

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review

    Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review mā Nizar M. Tannir, Sumanta K. Pal, Michael B. Atkins

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience

    Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience mā Umang Swami, Petros Grivas, Sumanta K. Pal, Neeraj Agarwal

    I whakaputaina 2021
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis

    Nephrotoxicity Associated with Contemporary Renal Cell Carcinoma Regimens: A Systematic Review and Meta-Analysis mā Akasha Dukkipati, Xiaochen Li, Sumanta K. Pal, Miguel Zugman

    I whakaputaina 2023
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe

    Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe mā Luís Meza, Paulo Gustavo Bergerot, Neeraj Agarwal, Sumanta K. Pal

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Carta
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Systemic therapy and COVID19: Immunotherapy and chemotherapy

    Systemic therapy and COVID19: Immunotherapy and chemotherapy mā Shuchi Gulati, Ramya Muddasani, Paulo Gustavo Bergerot, Sumanta K. Pal

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Overcoming Chemotherapy Resistance in Prostate Cancer

    Overcoming Chemotherapy Resistance in Prostate Cancer mā Ravi A. Madan, Sumanta K. Pal, Oliver Sartor, William L. Dahut

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Akt inhibitors in clinical development for the treatment of cancer

    Akt inhibitors in clinical development for the treatment of cancer mā Sumanta K. Pal, Karen L. Reckamp, Hua Yu, Robert A. Figlin

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Value-based genomics

    Value-based genomics mā Jun Gong, Kathy Pan, Marwan Fakih, Sumanta K. Pal, Ravi Salgia

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma

    Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma mā Alex Chehrazi‐Raffle, Tanya B. Dorff, Sumanta K. Pal, Yung Lyou

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: